Drug Profile
Research programme: musculoskeletal disorders therapies - Millenium Biologix Corporation
Alternative Names: ACTES™-B implants - Millenium Biologix Corporation; ACTES™-C implants - Millenium Biologix CorporationLatest Information Update: 02 Jun 2010
Price :
$50
*
At a glance
- Originator Millenium Biologix Corporation
- Class Cell therapies
- Mechanism of Action Cartilage replacements; Intercellular signalling peptide and protein stimulants; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cartilage disorders; Musculoskeletal disorders
Most Recent Events
- 06 Oct 2005 Early research in Cartilage disorders in Canada (Parenteral)
- 06 Oct 2005 Early research in Musculoskeletal disorders in Canada (Parenteral)